Table 1.

Key inclusion and exclusion criteria

Inclusion Criteria
All patients	-Male and female patients aged 18–75 years with signed and dated informed consent
	-Biopsy-proven primary FSGS or documented TRPC6 gene mutation causing FSGS
	-Mean UPCR ≥1000 mg/g
	-BMI ≤40 kg/m2
Corticosteroid therapy	-Stable dose for ≥4 weeks (if applicable)
ACEi/ARB/finerenone/ASI/SGLT2i treatment	-Stable dose for ≥4 weeks prior to screening, with no plan to change dose
Exclusion criteria
Diagnosis	-Known monogenic FSGS (except TRPC6) or clinical/histological evidence of secondary FSGS
	-Documented Alport syndrome, nail patella syndrome, diabetic nephropathy, IgA nephropathy, lupus nephritis, monoclonal gammopathy
	-Genitourinary malformations with vesicoureteral reflux or kidney dysplasia
	-History of organ transplantation or planned transplantation during the study
	-Uncontrolled hypertension (mean resting systolic blood pressure >160 mm Hg)
	-QTc intervals >450 ms in men or >470 ms in women
	-History of congenital long QT syndrome, previous drug-induced QT prolongation, or other risk factors for torsade de pointes
	-Graded cataracts
	-History of gastrointestinal surgery or disorders that could interfere with trial mediation absorption
	-History of relevant allergy or hypersensitivity according to the investigator’s clinical judgment
Concomitant therapy	-Calcineurin inhibitors
	-Cytotoxic agents (cyclophosphamide, chlorambucil) or CD20 monoclonal antibodies (e.g., rituximab) within five half-lives before screening
	-Metformin, dofetilide, dabigatran, or digoxin within 5 half-lives before screening
	-Strong inhibitors or inducers of CYP3A within 1 week or 5 half-lives before screening
Safety laboratory findings	-eGFR <30 ml/min/1.73 m2
	-ALT/AST >3 × ULN at screening

ACEi, angiotensin-converting enzyme inhibitor; ALT, alanine aminotransferase; ARB, angiotensin receptor blocker; ASI, aldosterone synthase inhibitor; AST, aspartate aminotransferase; BMI, body mass index; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; IgA, immunoglobulin A; SGLT2i, sodium-glucose cotransporter-2 inhibitor; TRPC6, transient receptor potential cation channel, subfamily C, member 6; ULN, upper limit of normal; UPCR, urinary protein:creatinine ratio.